Stifel lowered the firm’s price target on Inspire Medical (INSP) to $175 from $190 and keeps a Hold rating on the shares. While Inspire’s valuation has “become more attractive of late” and the company “appears well positioned for any tariff twists and turns,” the firm sees some “choppy waters ahead” and believes news flow might act as an overhang to Inspire shares over the next six months, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical adds Paul Hoff, Ruchir Patel as VP, senior medical directors
- Inspire Medical price target lowered to $216 from $234 at KeyBanc
- Inspire Medical price target lowered to $215 from $230 at Mizuho
- Inspire Medical price target lowered to $215 from $260 at RBC Capital
- Inspire Medical price target lowered to $210 from $235 at Truist